It is very generous for you to take the time to point out those posts, which are very interesting and helpful. I would only say that the more I read about p53 p21 PUMA etc the less clear it all seems.
It is also interesting that Phase 1 for the Aprea drug was not impressive, and yet in combo with Cisplat it may be a winner.
That suggests of course that less than sterling phase 1 for Kevetrin is not the be all or end all, just a beginning.